Neoadjuvant therapy
Impact of Neoadjuvant Endocrine Therapy on Tumor Transcriptome in Patients With Early-Stage Breast Cancer From the FLEX Trial
PUBLICATION: San Antonio Breast Cancer Symposium 2022 TITLE: Impact Read More
I-SPY2: ImPrint immune signature identifies ESBC patients who benefit from PD1 checkpoint inhibition
ASCO 2022, Poster #514 Authors: Kuilman et al.
Read MoreDurvalumab + olaparib + paclitaxel in High-risk HER2-negative ESBC: I-SPY2 trial results
I-SPY2 Trial, Cancer Cell 39, 989โ998, 2021 Authors: Pusztai et al.
Read MoreMolecular profiles of genomically High Risk ER+ HER2- breast cancer tumors classified as functionally Basal or Luminal B by the BluePrint
PUBLICATION: ASCO 2021 ย Authors Joyce OโShaughnessy1, Virginia G. Read More
5-year distant metastasis-free survival outcomes on the pre-operative use of MammaPrint and BluePrint for neoadjuvant decisions in the NBREaST II trial
Publication: St. Gallen Authors: E. Gรถker, M.P. Hendriks, M. van Read More
Pathologic Complete Response (pCR) Rates According to MammaPrint and BluePrint Results are Consistent Among Pre- and Post-Menopausal Patients
ย Publication: Miami Breastย Authors Pat Whitworth, James Read More
MammaPrint and BluePrint as prognostic indicators for elderly patients with early-stage breast cancer
PUBLICATION: SABCS 2020 AUTHORS: Peter W. Blumencranz, Mehran Habibi, Read More
Molecular subtyping by BluePrint improves prediction of treatment responses and survival outcomes in patients with discordant clinical and genomic classification
PUBLICATION: SABCS 2020 AUTHORS: Pat Whitworth, James V Pellicane, Jr., Read More
5-year outcomes in the NBRST trial: preoperative MammaPrint and BluePrint breast cancer subtype is associated with neoadjuvant treatment response and survival
ย PUBLICATION: SABCS 2020 AUTHORS: Pat Whitworth, James V Read More
I-SPY2: Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer
I-SPY2, JAMA Oncology, 2020 Authors: Yee et al.
Read More
